EXEL NASDAQ
Exelixis, Inc.
1W: +1.5%
1M: +12.0%
3M: +18.1%
YTD: +50.0%
1Y: +68.8%
3Y: +209.6%
5Y: +203.9%
$65.35
+0.24 (+0.37%)
Weekly Expected Move ±2.7%
$61
$63
$65
$66
$68
Credit Risk of going bust: lower than 92% of companies Debt: 1.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.05 (down 99.9%), Exelixis, Inc. would be worth roughly what it owes.
Total debt $165.9M against a stock market value of $16.43B.
Distance to default 15.71 (Merton model): prices to 2026-10-27, balance sheet 2026-07-03, debt counted $83.0M (short-term plus half of long-term), stock volatility 33.8%; Altman Z'' 7.72. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.05 (down 99.9%), Exelixis, Inc. would be worth roughly what it owes.
Total debt $165.9M against a stock market value of $16.43B.
Distance to default 15.71 (Merton model): prices to 2026-10-27, balance sheet 2026-07-03, debt counted $83.0M (short-term plus half of long-term), stock volatility 33.8%; Altman Z'' 7.72. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
4 bullish
0 neutral
0 bearish
Articles (7d)
4
Daily Sentiment (7 Days)
Articles (100)
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
Here's Why Exelixis (EXEL) is a Strong Value Stock
Exelixis, Inc. $EXEL Stock Position Cut by CX Institutional
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?
Exelixis, Inc. $EXEL Shares Bought by Envestnet Asset Management Inc.
Merck Welireg, Eisai Lenvima combo approved for kidney cancer
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Bank of America Corp DE Boosts Stake in Exelixis, Inc. $EXEL
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Integrated Wealth Concepts LLC Has $3.19 Million Stock Holdings in Exelixis, Inc. $EXEL
Integrated Wealth Concepts LLC Has $3.19 Million Stock Holdings in Exelixis, Inc. $EXEL
California State Teachers Retirement System Acquires 14,488,217 Shares of Exelixis, Inc. $EXEL
Exelixis, Inc. $EXEL Shares Sold by Hsbc Holdings PLC
Exelixis zanzalintinib NDA review extended three months by FDA
Baird Financial Group Inc. Raises Holdings in Exelixis, Inc. $EXEL
Baird Financial Group Inc. Raises Holdings in Exelixis, Inc. $EXEL
DD: $EXEL Short Thesis (gimme feedback)
DD: $EXEL Short Opportunity
DD: $EXEL Short Opportunity
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
Allworth Financial LP Takes Position in Exelixis, Inc. $EXEL
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Here's Why Exelixis (EXEL) is a Strong Value Stock
Quant ratings on Renaissance Technologies top holdings: NVDA, META, INTC
Exelixis (EXEL) Q2 2026 Earnings Call Transcript
Exelixis, Inc. $EXEL Shares Acquired by Assenagon Asset Management S.A.
Arkadios Wealth Advisors Purchases New Position in Exelixis, Inc. $EXEL
Amundi Sells 121,348 Shares of Exelixis, Inc. $EXEL
EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 View
Exelixis (EXEL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Exelixis (EXEL) Tops Q2 Earnings Estimates
Exelixis, Inc. $EXEL Stake Lowered by Caerus Investment Advisors LLC
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Bank of New York Mellon Corp Sells 57,995 Shares of Exelixis, Inc. $EXEL
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
Allspring Global Investments Holdings LLC Acquires 323,895 Shares of Exelixis, Inc. $EXEL
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised
3 Under-the-Radar Stocks to Buy and Hold
Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?
Stocks Look Shaky, But This Sector is Booming (Biotech)
Here's Why Exelixis (EXEL) is a Strong Growth Stock
EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue?
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Here's Why Exelixis (EXEL) is a Strong Value Stock
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
Prediction: This Stock Could Double By 2031
Exelixis (EXEL) is a Top-Ranked Momentum Stock: Should You Buy?
Prologis To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday
EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus
Here's Why Exelixis (EXEL) is a Strong Value Stock
Exelixis outlines December PDUFA timeline for ZANZA CRC filing while adding $750M buyback authorization
Exelixis (EXEL) Q1 2026 Earnings Transcript
Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Exelixis (EXEL) Tops Q1 Earnings Estimates
Exelixis Non-GAAP EPS of $0.87 beats by $0.11, revenue of $610.8M beats by $5.93M
Earnings Scheduled For May 5, 2026
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Near the top of biotech rankings, AbbVie's Q1 beat makes a case for more upside
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Why Is Merck Stock Falling Tuesday?
Why Is Merck Stock Falling Tuesday?
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Exelixis, Inc. $EXEL Shares Acquired by Merit Financial Group LLC
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Kura rises after early-stage trial data for kidney cancer therapy
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
SG Americas Securities LLC Buys 15,203 Shares of Exelixis, Inc. $EXEL
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
Trump may impose tariffs on drugmakers who haven't signed MFN deals - reports
Allspring Global Investments Holdings LLC Has $60.31 Million Position in Exelixis, Inc. $EXEL
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Exelixis: A Strong Contender in the Cancer Drug Market
Exelixis, Inc. $EXEL Stake Lowered by Assenagon Asset Management S.A.
Here's Why Exelixis (EXEL) is a Strong Value Stock
The Best Healthcare Stocks to Buy With $50 Right Now
Center For Asset Management LLC Purchases New Shares in Exelixis, Inc. $EXEL